Why Indomethacin Is Not Your Average Painkiller: the Hidden Power and Risks

Read in-depth coverage surrounding Why Indomethacin Is Not Your Average Painkiller: the Hidden Power and Risks.

While primarily recognized as a joint medication, indomethacin occupies an extraordinary niche in neurology. It is the absolute therapeutic touchstone for a class of primary headaches known as indomethacin-responsive headache disorders, most notably hemicrania continua and paroxysmal hemicrania.

Hemicrania continua causes a continuous, strictly unilateral head pain of fluctuating intensity, accompanied by autonomic symptoms like eye tearing, nasal congestion, and eyelid drooping. Other classic headache treatments, including sumatriptan, acetaminophen, and high-dose opioids, consistently fail to relieve it. Yet indomethacin eliminates the pain entirely.

This reaction is so uniform that neurologists use an "Indotest" as a formal diagnostic requirement: if a patient's strictly one-sided headache melts away within 48 hours of receiving indomethacin, the diagnosis is confirmed. Why indomethacin works where other NSAIDs fail remains under active investigation, though researchers point to its ability to uniquely decrease intracranial pressure and modulate blood flow within the internal carotid artery system.

In neonatal intensive care units, the drug performs an entirely different, lifesaving role. Intravenous indomethacin closes patent ductus arteriosus (PDA) in premature infants. PDA occurs when a critical fetal blood vessel connecting the pulmonary artery to the aorta fails to close naturally after birth. By blocking prostaglandins that keep the vessel dilated, indomethacin forces the ductus arteriosus to constrict, frequently sparing fragile newborns from open-chest surgical ligation.